G1 Therapeutics announced that new data from its randomized Phase 2 clinical trial of trilaciclib in combination with etoposide/carboplatin for treatment of first-line small cell lung cancer, or SCLC, will be presented at the European Society for Medical Oncology, or ESMO. The company reported topline data from this trial in March showing myelopreservation benefits. Additional data from this trial have been selected for a poster discussion session on October 21. A second poster with new data focused specifically on the impact of trilaciclib on immune system function, including preservation of T cell subsets such as activated CD8+ T cells and an increased CD8+/regulatory T cell ratio in peripheral blood compared to placebo, will be presented on October 20.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.